Publicly funded studies
Although the majority of our studies are funded by unconditional donations from the pharmaceutical industry, we are always keen to collaborate with academic colleagues on grant-funded projects. Some examples are provided below:
The DSRU was part of a pan-European consortium of 17 leading research institutions which took part in the ARITMO project (“Arrhythmogenic Potential of Drugs”), funded by the European Commission in the 7th Framework Programme (FP7). The aim of the ARITMO project was to analyse the arrhythmic potential of drugs in the following classes: antipsychotics, anti-infectives (antibacterials, antimycotics and antivirals) and H1-antihistamines, globally and in specific subgroups (age, co-morbidity, genetically). More detailed information is available here.
The DSRU is one of 15 partners taking part in the SAFEGUARD project (“Safety Evaluation of Adverse Reactions in Diabetes”), a large collaborative project funded by the European Commission via FP7. The aim of the project is to investigate an important public health issue: the pancreatic and cardiovascular/cerebrovascular safety of blood glucose-lowering drugs used in Type II diabetes mellitus. More detailed information is available here.
Yellow Card Patient Reporting Study
This collaborative research project evaluated the specific impact of patient reporting in the UK spontaneous reporting (Yellow Card) database. The project was funded by The National Institute for Health Research Health Technology Assessment programme. More detailed information is available here.
Drug Induced Arrhythmia Risk Evaluation (DARE) study
Funded by the British Heart Foundation. See the Registries page for further information and related publications below.
Signal Detection MPhil
The project was entitled “Combining quantitative and qualitative methods in signal detection and evaluation in Pharmacovigilance” and was funded by a grant from the Medicines and Healthcare Products Regulatory Agency (MHRA) Targeted Research Programme, in the form of a MPhil.